Advertisement

Advances in Ocular Toxoplasmosis

  • Arthur Braakenburg
  • Aniki Rothova

Abstract

Toxoplasma gondii is a ubiquitous organism able to infect almost all mammals and birds and has been estimated to infect one third of the global human population with a great variation of prevalence between different countries [1, 2]. Generally, ocular toxoplasmosis (OT) represents the most common cause of posterior uveitis. OT might develop as a complication of both acquired and congenital infections. OT may develop during the acute phase of infection, but is particularly characterized by active attacks and recurrences during the chronic phase. Severity of OT may be influenced by variations in the strain/genotype of T. gondii, parasitic load, infectious stage of parasite (infection by oocyst or tissue cyst), moment of infection (congenital or postnatally acquired), and host-related factors such as immune status and age [2, 3]. OT manifests typically as focal chorioretinitis with a tendency to recur in the adjacent retinal areas. The factors responsible for recurrences are unknown, but trauma, hormonal changes, and cellular and/or humoral immunosuppression appear to contribute to the release of parasites from tissue cysts [3]. In addition, autoimmune processes were also pointed out as possible (co-)factors for the recurrences and severity of OT [4, 5]. The prevalence of recurrences was reported to be 55 % in 5 years of follow-up after the first episode [6]. Holland et al. reported that the risk of recurrence was the highest immediately after an episode of active disease and that recurrence had a tendency to occur in clusters [7]. Further, younger patients had a higher risk on an active OT episode compared to older patients [8]. Treatment for OT commonly includes a combination of various systemic antiparasitic drugs sometimes with addition of corticosteroids to lessen the inflammatory reaction and its possible complications [3]. Visual prognosis is mainly determined by the location of the retinal lesion; macular lesions and lesions adjacent to the optic disk have a worse visual prognosis.

Keywords

Bacterial Vaginosis Immunocompetent Host Posterior Uveitis Tissue Cyst Retinal Lesion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Robert-Gangneux F, Darde ML. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012;25:264–96.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Hill D, Dubey JP. Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect. 2002;8:634–40.CrossRefPubMedGoogle Scholar
  3. 3.
    Holland GN. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. Am J Ophthalmol. 2004;137:1–17.PubMedGoogle Scholar
  4. 4.
    Garweg JG. Immunopathology in ocular toxoplasmosis: facts and clues. Mem Inst Oswaldo Cruz. 2009;104:211–20.CrossRefPubMedGoogle Scholar
  5. 5.
    Vallochi AL, da Silva Rios L, Nakamura MV, Silveira C, Muccioli C, Martins MC, Jr Belfort R, Rizzo LV. The involvement of autoimmunity against retinal antigens in determining disease severity in toxoplasmosis. J Autoimmun. 2005;24(1):25–32.CrossRefPubMedGoogle Scholar
  6. 6.
    Bosch-Driessen LE, Berendschot TT, Ongkosuwito JV, Rothova A. Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology. 2002;109:869–78.CrossRefPubMedGoogle Scholar
  7. 7.
    Holland GN, Crespi CM, ten Dam-van LN, et al. Analysis of recurrence patterns associated with toxoplasmic retinochoroiditis. Am J Ophthalmol. 2008;145:1007–13.CrossRefPubMedGoogle Scholar
  8. 8.
    Garweg JG, Scherrer JN, Halberstadt M. Recurrence characteristics in European patients with ocular toxoplasmosis. Br J Ophthalmol. 2008;92:1253–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Bahia-Oliveira LM, Jones JL, zevedo-Silva J, Alves CC, Orefice F, Addiss DG. Highly endemic, waterborne toxoplasmosis in north Rio de Janeiro state, Brazil. Emerg Infect Dis. 2003;9:55–62.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Balasundaram MB, Andavar R, Palaniswamy M, Venkatapathy N. Outbreak of acquired ocular toxoplasmosis involving 248 patients. Arch Ophthalmol. 2010;128:28–32.CrossRefPubMedGoogle Scholar
  11. 11.
    Bowie WR, King AS, Werker DH, et al. Outbreak of toxoplasmosis associated with municipal drinking water. The BC Toxoplasma Investigation Team. Lancet. 1997;350:173–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Kijlstra A, Eissen OA, Cornelissen J, Munniksma K, Eijck I, Kortbeek T. Toxoplasma gondii infection in animal-friendly pig production systems. Invest Ophthalmol Vis Sci. 2004;45:3165–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Kijlstra A, Meerburg B, Cornelissen J, De CS, Vereijken P, Jongert E. The role of rodents and shrews in the transmission of Toxoplasma gondii to pigs. Vet Parasitol. 2008;156:183–90.CrossRefPubMedGoogle Scholar
  14. 14.
    Weigel RM, Dubey JP, Siegel AM, et al. Risk factors for transmission of Toxoplasma gondii on swine farms in Illinois. J Parasitol. 1995;81:736–41.CrossRefPubMedGoogle Scholar
  15. 15.
    Dubey JP, Lago EG, Gennari SM, Su C, Jones JL. Toxoplasmosis in humans and animals in Brazil: high prevalence, high burden of disease, and epidemiology. Parasitology. 2012;139:1375–424.CrossRefPubMedGoogle Scholar
  16. 16.
    Yang P, Zhang Z, Zhou H, et al. Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China. Curr Eye Res. 2005;30:943–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Biswas J, Narain S, Das D, Ganesh SK. Pattern of uveitis in a referral uveitis clinic in India. Int Ophthalmol. 1996;20:223–8.PubMedGoogle Scholar
  18. 18.
    Ronday MJ, Stilma JS, Barbe RF, et al. Aetiology of uveitis in Sierra Leone, west Africa. Br J Ophthalmol. 1996;80:956–61.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Kongyai N, Pathanapitoon K, Sirirungsi W, Kunavisarut P, de Groot-Mijnes JD, Rothova A. Infectious causes of posterior uveitis and panuveitis in Thailand. Jpn J Ophthalmol. 2012;56:390–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Garweg JG, Scherrer J, Wallon M, Kodjikian L, Peyron F. Reactivation of ocular toxoplasmosis during pregnancy. BJOG. 2005;112:241–2.CrossRefPubMedGoogle Scholar
  21. 21.
    Kump LI, Androudi SN, Foster CS. Ocular toxoplasmosis in pregnancy. Clin Experiment Ophthalmol. 2005;33:455–60.CrossRefPubMedGoogle Scholar
  22. 22.
    Dubey JP, Lindsay DS, Speer CA. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev. 1998;11:267–99.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Dabritz HA, Gardner IA, Miller MA, et al. Evaluation of two Toxoplasma gondii serologic tests used in a serosurvey of domestic cats in California. J Parasitol. 2007;93:806–16.CrossRefPubMedGoogle Scholar
  24. 24.
    Dabritz HA, Conrad PA. Cats and Toxoplasma: implications for public health. Zoonoses Public Health. 2010;57:34–52.CrossRefPubMedGoogle Scholar
  25. 25.
    Dodds EM, Holland GN, Stanford MR, et al. Intraocular inflammation associated with ocular toxoplasmosis: relationships at initial examination. Am J Ophthalmol. 2008;146:856–65.CrossRefPubMedGoogle Scholar
  26. 26.
    Johnson MW, Greven GM, Jaffe GJ, Sudhalkar H, Vine AK. A typical, severe toxoplasmic retinochoroiditis in elderly patients. Ophthalmology. 1997;104:48–57.CrossRefPubMedGoogle Scholar
  27. 27.
    Labalette P, Delhaes L, Margaron F, Fortier B, Rouland JF. Ocular toxoplasmosis after the fifth decade. Am J Ophthalmol. 2002;133:506–15.CrossRefPubMedGoogle Scholar
  28. 28.
    Ajzenberg D, Cogne N, Paris L, et al. Genotype of 86 Toxoplasma gondii isolates associated with human congenital toxoplasmosis, and correlation with clinical findings. J Infect Dis. 2002;186:684–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Ajzenberg D, Yera H, Marty P, et al. Genotype of 88 Toxoplasma gondii isolates associated with toxoplasmosis in immunocompromised patients and correlation with clinical findings. J Infect Dis. 2009;199:1155–67.CrossRefPubMedGoogle Scholar
  30. 30.
    Fekkar A, Ajzenberg D, Bodaghi B, et al. Direct genotyping of Toxoplasma gondii in ocular fluid samples from 20 patients with ocular toxoplasmosis: predominance of type II in France. J Clin Microbiol. 2011;49:1513–7.PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Howe DK, Sibley LD. Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease. J Infect Dis. 1995;172:1561–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Nowakowska D, Colon I, Remington JS, et al. Genotyping of Toxoplasma gondii by multiplex PCR and peptide-based serological testing of samples from infants in Poland diagnosed with congenital toxoplasmosis. J Clin Microbiol. 2006;44:1382–9.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Carneiro AC, Andrade GM, Costa JG, et al. Genetic characterization of Toxoplasma gondii revealed highly diverse genotypes for isolates from newborns with congenital toxoplasmosis in southeastern Brazil. J Clin Microbiol. 2013;51:901–7.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Ferreira AM, Vitor RW, Gazzinelli RT, Melo MN. Genetic analysis of natural recombinant Brazilian Toxoplasma gondii strains by multilocus PCR-RFLP. Infect Genet Evol. 2006;6:22–31.CrossRefGoogle Scholar
  35. 35.
    Khan A, Jordan C, Muccioli C, et al. Genetic divergence of Toxoplasma gondii strains associated with ocular toxoplasmosis, Brazil. Emerg Infect Dis. 2006;12:942–9.PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Sibley LD, Boothroyd JC. Virulent strains of Toxoplasma gondii comprise a single clonal lineage. Nature. 1992;359:82–5.CrossRefPubMedGoogle Scholar
  37. 37.
    Robben PM, Mordue DG, Truscott SM, Takeda K, Akira S, Sibley LD. Production of IL-12 by macrophages infected with Toxoplasma gondii depends on the parasite genotype. J Immunol. 2004;172:3686–94.CrossRefPubMedGoogle Scholar
  38. 38.
    Grigg ME, Ganatra J, Boothroyd JC, Margolis TP. Unusual abundance of atypical strains associated with human ocular toxoplasmosis. J Infect Dis. 2001;184:633–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Carme B, Bissuel F, Ajzenberg D, et al. Severe acquired toxoplasmosis in immunocompetent adult patients in French Guiana. J Clin Microbiol. 2002;40:4037–44.PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Carme B, Demar M, Ajzenberg D, Darde ML. Severe acquired toxoplasmosis caused by wild cycle of Toxoplasma gondii, French Guiana. Emerg Infect Dis. 2009;15:656–8.PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Demar M, Hommel D, Djossou F, et al. Acute toxoplasmoses in immunocompetent patients hospitalized in an intensive care unit in french Guiana. Clin Microbiol Infect. 2012;18:E221–31.CrossRefPubMedGoogle Scholar
  42. 42.
    Gilbert RE, Freeman K, Lago EG, et al. Ocular sequelae of congenital toxoplasmosis in Brazil compared with Europe. PLoS Negl Trop Dis. 2008;2, e277.PubMedCentralCrossRefPubMedGoogle Scholar
  43. 43.
    Mets MB, Holfels E, Boyer KM, et al. Eye manifestations of congenital toxoplasmosis. Am J Ophthalmol. 1997;123:1–16.CrossRefPubMedGoogle Scholar
  44. 44.
    Elkins BS, Holland GN, Opremcak EM, et al. Ocular toxoplasmosis misdiagnosed as cytomegalovirus retinopathy in immunocompromised patients. Ophthalmology. 1994;101:499–507.CrossRefPubMedGoogle Scholar
  45. 45.
    Holland GN, Engstrom Jr RE, Glasgow BJ, et al. Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1988;106:653–67.CrossRefPubMedGoogle Scholar
  46. 46.
    Holland GN. Ocular toxoplasmosis in the immunocompromised host. Int Ophthalmol. 1989;13:399–402.CrossRefPubMedGoogle Scholar
  47. 47.
    Fekkar A, Bodaghi B, Touafek F, Le HP, Mazier D, Paris L. Comparison of immunoblotting, calculation of the Goldmann-Witmer coefficient, and real-time PCR using aqueous humor samples for diagnosis of ocular toxoplasmosis. J Clin Microbiol. 2008;46:1965–7.PubMedCentralCrossRefPubMedGoogle Scholar
  48. 48.
    Westeneng AC, Rothova A, de Boer JH, de Groot-Mijnes JD. Infectious uveitis in immunocompromised patients and the diagnostic value of polymerase chain reaction and Goldmann-Witmer coefficient in aqueous analysis. Am J Ophthalmol. 2007;144:781–5.CrossRefPubMedGoogle Scholar
  49. 49.
    Rothova A, de Boer JH, Ten Dam-van Loon NH, et al. Usefulness of aqueous humor analysis for the diagnosis of posterior uveitis. Ophthalmology. 2008;115:306–11.CrossRefPubMedGoogle Scholar
  50. 50.
    Gras L, Gilbert RE, Wallon M, Peyron F, Cortina-Borja M. Duration of the IgM response in women acquiring Toxoplasma gondii during pregnancy: implications for clinical practice and cross-sectional incidence studies. Epidemiol Infect. 2004;132:541–8.PubMedCentralCrossRefPubMedGoogle Scholar
  51. 51.
    Gilbert RE, Gras L, Wallon M, Peyron F, Ades AE, Dunn DT. Effect of prenatal treatment on mother to child transmission of Toxoplasma gondii: retrospective cohort study of 554 mother-child pairs in Lyon, France. Int J Epidemiol. 2001;30:1303–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Rothova A, Buitenhuis HJ, Meenken C, et al. Therapy of ocular toxoplasmosis. Int Ophthalmol. 1989;13(6):415–9.Google Scholar
  53. 53.
    Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol. 2002;134:34–40.CrossRefPubMedGoogle Scholar
  54. 54.
    Soheilian M, Sadoughi MM, Ghajarnia M, et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology. 2005;112:1876–82.CrossRefPubMedGoogle Scholar
  55. 55.
    Gormley PD, Pavesio CE, Minnasian D, Lightman S. Effects of drug therapy on Toxoplasma cysts in an animal model of acute and chronic disease. Invest Ophthalmol Vis Sci. 1998;39:1171–5.PubMedGoogle Scholar
  56. 56.
    Winterhalter S, Severing K, Stammen J, Maier AK, Godehardt E, Joussen AM. Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis? Graefes Arch Clin Exp Ophthalmol. 2010;248:1187–92.CrossRefPubMedGoogle Scholar
  57. 57.
    Iaccheri B, Fiore T, Papadaki T, et al. Adverse drug reactions to treatments for ocular toxoplasmosis: a retrospective chart review. Clin Ther. 2008;30:2069–74.CrossRefPubMedGoogle Scholar
  58. 58.
    McLeod R, Boyer K, Karrison T, et al. Outcome of treatment for congenital toxoplasmosis, 1981–2004: the national collaborative Chicago-based, congenital toxoplasmosis study. Clin Infect Dis. 2006;42:1383–94.CrossRefPubMedGoogle Scholar
  59. 59.
    Kaye A. Toxoplasmosis: diagnosis, treatment, and prevention in congenitally exposed infants. J Pediatr Health Care. 2011;25:355–64.CrossRefPubMedGoogle Scholar
  60. 60.
    Nijhawan R, Bansal R, Gupta N, Beke N, Kulkarni P, Gupta A. Intraocular cysts of Toxoplasma gondii in patients with necrotizing retinitis following periocular/intraocular triamcinolone injection. Ocul Immunol Inflamm. 2013.Google Scholar
  61. 61.
    Ronday MJ, Luyendijk L, Baarsma GS, Bollemeijer JG, Van der Lelij A, Rothova A. Presumed acquired ocular toxoplasmosis. Arch Ophthalmol. 1995;113:1524–9.CrossRefPubMedGoogle Scholar
  62. 62.
    Braakenburg AM, Rothova A. Clinical features of ocular toxoplasmosis during pregnancy. Retina. 2009;29:627–30.CrossRefPubMedGoogle Scholar
  63. 63.
    O’Connor GR, Frenkel JK. Editorial: dangers of steroid treatment in toxoplasmosis. Periocular injections and systemic therapy. Arch Ophthalmol. 1976;94:213.CrossRefPubMedGoogle Scholar
  64. 64.
    Bar-Oz B, Weber-Schoendorfer C, Berlin M, et al. The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: a prospective, multicentre, observational study. Drug Saf. 2012;35:589–98.CrossRefPubMedGoogle Scholar
  65. 65.
    Sarkar M, Woodland C, Koren G, Einarson AR. Pregnancy outcome following gestational exposure to azithromycin. BMC Pregnancy Childbirth. 2006;6:18.PubMedCentralCrossRefPubMedGoogle Scholar
  66. 66.
    Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet. 2003;361:983–8.CrossRefPubMedGoogle Scholar
  67. 67.
    Ugwumadu A, Reid F, Hay P, Manyonda I. Natural history of bacterial vaginosis and intermediate flora in pregnancy and effect of oral clindamycin. Obstet Gynecol. 2004;104:114–9.CrossRefPubMedGoogle Scholar
  68. 68.
    Lasave AF, az-Llopis M, Muccioli C, Belfort R, Jr Arevalo JF. Intravitreal clindamycin and Dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months. Ophthalmology. 2010;117:1831–8.CrossRefPubMedGoogle Scholar
  69. 69.
    Sobrin L, Kump LI, Foster CS. Intravitreal clindamycin for toxoplasmic retinochoroiditis. Retina. 2007;27:952–7.CrossRefPubMedGoogle Scholar
  70. 70.
    Baharivand N, Mahdavifard A, Fouladi RF. Intravitreal clindamycin plus Dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial. Int Ophthalmol. 2013;33:39–46.CrossRefPubMedGoogle Scholar
  71. 71.
    Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of Intravitreal clindamycin and Dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011;118:134–41.CrossRefPubMedGoogle Scholar
  72. 72.
    Gagliuso DJ, Teich SA, Friedman AH, Orellana J. Ocular toxoplasmosis in AIDS patients. Trans Am Ophthalmol Soc. 1990;88:63–86.PubMedCentralPubMedGoogle Scholar
  73. 73.
    Silveira C, Belfort Jr R, Muccioli C, et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol. 2002;134:41–6.CrossRefPubMedGoogle Scholar
  74. 74.
    Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the national institutes of health, and the HIV medicine association of the infectious diseases society of america. MMWR Recomm Rep. 2009;58:1–207.Google Scholar
  75. 75.
    Baden LR, Katz JT, Franck L, Tsang S, Hall M, Rubin RH, Jarcho J. Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprim-sulfamethoxazole. Transplantation. 2003;75(3):339–43.CrossRefPubMedGoogle Scholar
  76. 76.
    Gourishankar S, Doucette K, Fenton J, Purych D, Kowalewska-Grochowska K, Preiksaitis J. The use of donor and recipient screening for toxoplasma in the era of universal trimethoprim sulfamethoxazole prophylaxis. Transplantation. 2008;85:980–5.CrossRefPubMedGoogle Scholar
  77. 77.
    Lopez A, Dietz VJ, Wilson M, Navin TR, Jones JL. Preventing congenital toxoplasmosis. MMWR Recomm Rep. 2000;49:59–68.PubMedGoogle Scholar
  78. 78.
    Dubey JP, Kotula AW, Sharar A, Andrews CD, Lindsay DS. Effect of high temperature on infectivity of Toxoplasma gondii tissue cysts in pork. J Parasitol. 1990;76:201–4.CrossRefPubMedGoogle Scholar
  79. 79.
    El-Nawawi FA, Tawfik MA, Shaapan RM. Methods for inactivation of Toxoplasma gondii cysts in meat and tissues of experimentally infected sheep. Foodborne Pathog Dis. 2008;5:687–90.CrossRefPubMedGoogle Scholar
  80. 80.
    Palanisamy M, Madhavan B, Balasundaram MB, Andavar R, Venkatapathy N. Outbreak of ocular toxoplasmosis in Coimbatore, India. Indian J Ophthalmol. 2006;54:129–31.CrossRefPubMedGoogle Scholar
  81. 81.
    Balaskas K, Vaudaux J, Boillat-Blanco N, Guex-Crosier Y. Azithromycin versus sulfadiazine and pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study. Med Sci Monit. 2012;18:CR296–302.PubMedCentralCrossRefPubMedGoogle Scholar
  82. 82.
    Pearson PA, Piracha AR, Sen HA, Jaffe GJ. Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients. Ophthalmology. 1999;106:148–53.CrossRefPubMedGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  1. 1.Department of OphthalmologyVU University Medical Center AmsterdamAmsterdamThe Netherlands
  2. 2.Department of OphthalmologyErasmus Medical Centre RotterdamRotterdamThe Netherlands

Personalised recommendations